Cerus CORP 10-Q quarterly reports

Cerus Corporation reports increased product revenue in Q2 2026, driven by higher sales volumes for its INTERCEPT Blood System kits and IFC, while net loss narrows.

Cerus Corporation reported a 23% increase in total revenue to $59.9 million for the first quarter of 2026, driven by growth in platelet and IFC product sales.

Cerus Corporation reported a significant reduction in net loss for the third quarter and first nine months of 2025, driven by robust product and government contract revenue increases, despite ongoing development challenges for its red blood cell system and increased operating expenses.

Cerus Corporation reported increased product and government contract revenue for Q2 2025, but faced a regulatory setback for its red blood cell system and a shift to negative operating cash flow.

Cerus Corporation announces a 13% increase in total revenue for the first quarter of 2025, driven by growth in U.S. platelet kit sales.

Cerus Corporation's third quarter results show an increase in product revenue but a decrease in government contract revenue, with ongoing development of the red blood cell system.

Cerus Corporation's second quarter 2024 results show a 20% increase in product revenue compared to the same period last year, driven by growth in U.S. platelet sales.

Cerus Corporation's first quarter 2024 results show a 24% increase in product revenue, driven by U.S. sales, while government contract revenue declined.